Halozyme Therapeutics, Inc. (NASDAQ:HALO) Shares Bought by Captrust Financial Advisors

Captrust Financial Advisors lifted its holdings in Halozyme Therapeutics, Inc. (NASDAQ:HALO) by 24.3% in the 4th quarter, Holdings Channel.com reports. The fund owned 29,862 shares of the biopharmaceutical company’s stock after buying an additional 5,829 shares during the quarter. Captrust Financial Advisors’ holdings in Halozyme Therapeutics were worth $1,428,000 at the end of the most recent quarter.

Several other large investors also recently made changes to their positions in the business. Vanguard Group Inc. increased its position in shares of Halozyme Therapeutics by 3.0% in the fourth quarter. Vanguard Group Inc. now owns 13,281,714 shares of the biopharmaceutical company’s stock worth $634,999,000 after acquiring an additional 386,618 shares in the last quarter. Snyder Capital Management L P increased its position in shares of Halozyme Therapeutics by 2.6% in the fourth quarter. Snyder Capital Management L P now owns 4,168,453 shares of the biopharmaceutical company’s stock worth $199,294,000 after acquiring an additional 105,086 shares in the last quarter. Dimensional Fund Advisors LP increased its position in shares of Halozyme Therapeutics by 2.5% in the fourth quarter. Dimensional Fund Advisors LP now owns 1,933,560 shares of the biopharmaceutical company’s stock worth $92,446,000 after acquiring an additional 47,795 shares in the last quarter. Northern Trust Corp boosted its stake in shares of Halozyme Therapeutics by 8.7% in the fourth quarter. Northern Trust Corp now owns 1,827,771 shares of the biopharmaceutical company’s stock valued at $87,386,000 after purchasing an additional 145,617 shares during the period. Finally, Charles Schwab Investment Management Inc. boosted its stake in shares of Halozyme Therapeutics by 0.6% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 1,783,177 shares of the biopharmaceutical company’s stock valued at $85,254,000 after purchasing an additional 9,780 shares during the period. Institutional investors and hedge funds own 97.79% of the company’s stock.

Halozyme Therapeutics Trading Down 24.6%

NASDAQ HALO opened at $50.23 on Wednesday. Halozyme Therapeutics, Inc. has a 12 month low of $42.01 and a 12 month high of $70.51. The company has a debt-to-equity ratio of 4.14, a current ratio of 7.80 and a quick ratio of 9.15. The company has a market capitalization of $6.19 billion, a price-to-earnings ratio of 14.64, a price-to-earnings-growth ratio of 0.42 and a beta of 1.26. The company’s fifty day moving average price is $61.39 and its two-hundred day moving average price is $55.96.

Halozyme Therapeutics (NASDAQ:HALO) last posted its quarterly earnings results on Tuesday, May 6th. The biopharmaceutical company reported $1.11 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.98 by $0.13. Halozyme Therapeutics had a net margin of 43.74% and a return on equity of 157.78%. The company had revenue of $264.86 million for the quarter, compared to the consensus estimate of $231.21 million. During the same period last year, the firm posted $0.79 EPS. The company’s revenue for the quarter was up 35.2% on a year-over-year basis. As a group, research analysts predict that Halozyme Therapeutics, Inc. will post 4.73 earnings per share for the current fiscal year.

Insider Transactions at Halozyme Therapeutics

In other news, Director Jeffrey William Henderson sold 4,497 shares of the firm’s stock in a transaction dated Monday, April 28th. The shares were sold at an average price of $60.37, for a total value of $271,483.89. Following the transaction, the director now directly owns 28,611 shares in the company, valued at approximately $1,727,246.07. This trade represents a 13.58% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, SVP Michael J. Labarre sold 1,697 shares of the firm’s stock in a transaction dated Thursday, February 27th. The stock was sold at an average price of $58.28, for a total transaction of $98,901.16. Following the completion of the transaction, the senior vice president now owns 173,756 shares in the company, valued at approximately $10,126,499.68. The trade was a 0.97% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 21,697 shares of company stock worth $1,276,552. 2.40% of the stock is currently owned by insiders.

Wall Street Analysts Forecast Growth

Several research analysts have recently weighed in on HALO shares. JPMorgan Chase & Co. upped their target price on shares of Halozyme Therapeutics from $55.00 to $58.00 and gave the company a “neutral” rating in a research note on Monday, April 21st. Wells Fargo & Company upped their target price on shares of Halozyme Therapeutics from $60.00 to $65.00 and gave the company an “equal weight” rating in a research note on Wednesday, May 7th. Benchmark downgraded shares of Halozyme Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, May 7th. HC Wainwright restated a “buy” rating and issued a $72.00 target price on shares of Halozyme Therapeutics in a research note on Friday, April 25th. Finally, Leerink Partners downgraded shares of Halozyme Therapeutics from a “market perform” rating to an “underperform” rating and set a $47.00 target price for the company. in a research note on Tuesday. One research analyst has rated the stock with a sell rating, five have assigned a hold rating and five have given a buy rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Hold” and a consensus target price of $62.10.

Halozyme Therapeutics Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.